市場調査レポート
商品コード
1310759

ユーイング肉腫の世界市場:上市済み薬品とパイプライン薬品の評価、臨床試験、競合情勢

Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

出版日: | 発行: GlobalData | ページ情報: 英文 74 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
ユーイング肉腫の世界市場:上市済み薬品とパイプライン薬品の評価、臨床試験、競合情勢
出版日: 2023年06月30日
発行: GlobalData
ページ情報: 英文 74 Pages
納期: 即納可能 即納可能とは
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のユーイング肉腫市場について調査分析し、疾患の情勢、上市済み薬品とパイプライン薬品の評価、現在と将来の競合情勢などを提供しています。

目次

第1章 序文

第2章 主な調査結果

第3章 疾患の情勢

  • 疾患の概要
  • 疫学の概要
  • 治療の概要

第4章 上市済み薬品の評価

  • 主な上市済み薬品
  • 概要:作用機序別
  • 概要:投与経路別
  • 上市済み薬品のプロファイルと売上予測

第5章 価格設定と償還の評価

  • 年間治療費
  • 価格設定と償還までの時間

第6章 パイプライン薬品の評価

  • フェーズ3パイプライン薬品
  • 概要:開発段階別
  • 概要:分子タイプ別
  • 概要:作用機序別
  • 概要:投与経路別
  • 薬品固有のフェーズ移行成功率(PTSR)と承認可能性(LoA)
  • 治療領域と適応症固有のPTSRとLoA

第7章 臨床試験の評価

  • 過去の概要
  • 概要:フェーズ別
  • 概要:ステータス別
  • 概要:進行中・計画中の試験のフェーズ別
  • 仮想コンポーネントを使用した試験
  • 地理的概要
  • 単一国・多国間試験:地域別
  • 内訳:上位20のスポンサーとフェーズ別
  • 内訳:上位20のスポンサーのステータス別
  • 概要:エンドポイントステータス別
  • 概要:人種・民族別
  • 登録データ
  • 試験施設の上位20か国
  • 世界の上位20施設
  • 実現可能性分析 - 地理的概要
  • 実現可能性分析 - ベンチマークモデル

第8章 取引情勢

  • 合併、買収、戦略的提携:地域別
  • 最近の合併、買収、戦略的提携

第9章 商業的評価

  • 主な市場企業

第10章 将来の市場カタリスト

第11章 付録

目次
Product Code: GDHC119CL

Abstract

This reports provides a data-driven overview of the current and future competitive landscape in Ewing Sarcoma therapeutics.

  • There will be only 9,457 diagnosed prevalent cases of ES in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for ES.
  • There are currently 11 marketed drugs for ES, the majority of which are DNA synthesis inhibitors.
  • R&D activity in ES is very strong in mid-stage, with 32 drugs in Phase II of development.
  • Clinical trial activity in ES was substantial during the past 10 years with 193 trials conducted overall.
  • Partnerships were the most common deal type executed globally in the ES space.

Scope

GlobalData's Ewing Sarcoma: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Ewing Sarcoma market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Ewing Sarcoma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

  • 1.1 Contents
  • 1.2 Report Scope
  • 1.3 List of Tables and Figures
  • 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

  • 3.1 Disease Overview
  • 3.2 Epidemiology Overview
  • 3.3 Treatment Overview

4 Marketed Drugs Assessment

  • 4.1 Leading Marketed Drugs
  • 4.2 Overview by Mechanism of Action
  • 4.3 Overview by Route of Administration
  • 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

  • 5.1 Annual Therapy Cost
  • 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

  • 6.1 Phase III Pipeline Drugs
  • 6.2 Overview by Development Stage
  • 6.3 Overview by Molecule Type
  • 6.4 Overview by Mechanism of Action
  • 6.5 Overview by Route of Administration
  • 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
  • 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

  • 7.1 Historical Overview
  • 7.2 Overview by Phase
  • 7.3 Overview by Status
  • 7.4 Overview by Phase for Ongoing and Planned Trials
  • 7.5 Trials with Virtual Components
  • 7.6 Geographic Overview
  • 7.7 Single-Country and Multinational Trials by Region
  • 7.8 Top 20 Sponsors with Breakdown by Phase
  • 7.9 Top 20 Sponsors with Breakdown by Status
  • 7.10 Overview by Endpoint Status
  • 7.11 Overview by Race and Ethnicity
  • 7.12 Enrollment Data
  • 7.13 Top 20 countries for Trial Sites
  • 7.14 Top 20 Sites Globally
  • 7.15 Feasibility Analysis - Geographic Overview
  • 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

  • 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
  • 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

  • 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

  • 11.1 Methodology
  • 11.2 Methodology - Sales Forecast
  • 11.3 Methodology - Pricing and Reimbursement
  • 11.4 Methodology - PTSR and LoA Analysis
  • 11.5 About the Authors
  • 11.6 Contact Us
  • 11.7 Disclaimer